PMID- 2138399
OWN - NLM
STAT- MEDLINE
DCOM- 19900416
LR  - 20190716
IS  - 0001-5598 (Print)
IS  - 0001-5598 (Linking)
VI  - 122
IP  - 2
DP  - 1990 Feb
TI  - Vasopressin enhances the clearance of beta-endorphin immunoreactivity from rat 
      cerebrospinal fluid.
PG  - 191-200
AB  - The effect of intracerebroventricular (lateral ventricle) administration of 
      arginine8-vasopressin (AVP) on the concentration of beta-endorphin 
      immunoreactivity in the cerebrospinal fluid obtained from the cisterna magna was 
      studied in rats. A decrease was observed 5 min following injection of 0.9 fmol 
      AVP. No statistically significant changes were found 5 min after 
      intracerebroventricular treatment of rats with 0.09 or 9 fmol. The decrease 
      induced by 0.9 fmol AVP was of short duration and was found 5 min after treatment 
      but not 10 and 20 min. Desglycinamide9-AVP (0.97 fmol), [pGlu4, Cyt6]-AVP-(4-9) 
      (1.44 fmol), N alpha-acetyl-AVP (0.88 fmol), lysine8-vasopressin (0.94 fmol) and 
      oxytocin (1 fmol) when intracerebroventricularly injected did not affect the 
      levels of beta-endorphin immunoreactivity in the cerebrospinal fluid 5 min later. 
      This suggests that the intact AVP-(1-9) molecule is required for this effect. 
      Intracerebroventricular pretreatment of rats with the vasopressin V1-receptor 
      antagonist d(CH2)5Tyr(Me)AVP (8.63 fmol) completely blocked the effect of AVP 
      (0.9 fmol). In order to investigate further the underlying mechanism, the effect 
      of AVP on the disappearance from the cerebrospinal fluid of exogenously applied 
      beta-endorphin was determined. Following intracerebroventricular injection of 
      1.46 pmol camel beta-endorphin-(1-31), the beta-endorphin immunoreactivity levels 
      in the cisternal cerebrospinal fluid increased rapidly, and reached peak values 
      at 10 min. The disappearance of beta-endorphin immunoreactivity from the 
      cerebrospinal fluid then followed a biphasic pattern with calculated half-lives 
      of 28 and 131 min for the initial and the terminal phase, respectively. Treatment 
      of rats with AVP (0.9 fmol; icv) during either phase (10, 30, 55 min following 
      intracerebroventricular administration of 1.46 pmol beta-endorphin-(1-31)) 
      significantly enhanced the disappearance of beta-endorphin immunoreactivity from 
      the cerebrospinal fluid. The data suggest that vasopressin plays a role in the 
      regulation of beta-endorphin levels in the cerebrospinal fluid by modulating 
      clearance mechanisms via V1-receptors in the brain.
FAU - Sweep, C G
AU  - Sweep CG
AD  - Rudolf Magnus Institute, Department of Pharmacology, Medical Faculty, University 
      of Utrecht, The Netherlands.
FAU - Boomkamp, M D
AU  - Boomkamp MD
FAU - Barna, I
AU  - Barna I
FAU - Logtenberg, A W
AU  - Logtenberg AW
FAU - Wiegant, V M
AU  - Wiegant VM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Denmark
TA  - Acta Endocrinol (Copenh)
JT  - Acta endocrinologica
JID - 0370312
RN  - 0 (Immune Sera)
RN  - 0 (Receptors, Angiotensin)
RN  - 0 (Receptors, Vasopressin)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 60617-12-1 (beta-Endorphin)
SB  - IM
MH  - Animals
MH  - Arginine Vasopressin/*administration & dosage/physiology
MH  - Cerebral Ventricles/metabolism
MH  - Immune Sera/analysis
MH  - Injections, Intraventricular
MH  - Male
MH  - Radioimmunoassay
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Angiotensin/physiology
MH  - Receptors, Vasopressin
MH  - Time Factors
MH  - beta-Endorphin/*cerebrospinal fluid
EDAT- 1990/02/01 00:00
MHDA- 1990/02/01 00:01
CRDT- 1990/02/01 00:00
PHST- 1990/02/01 00:00 [pubmed]
PHST- 1990/02/01 00:01 [medline]
PHST- 1990/02/01 00:00 [entrez]
AID - 10.1530/acta.0.1220191 [doi]
PST - ppublish
SO  - Acta Endocrinol (Copenh). 1990 Feb;122(2):191-200. doi: 10.1530/acta.0.1220191.